Evidence map›Paper›PMID 29894816›Full record

ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2019

Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.

In Heon Lee, Matthew S Palombo, Xiaoping Zhang, Zoltan Szekely, Patrick J Sinko

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  5. Virus Entry Inhibitors: Past, Present, and Future.Advances in experimental medicine and biology · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

In Heon LeeDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Rd, Piscataway, NJ 08854, USA. Electronic address: inheon@rutgers.edu.
Matthew S PalomboDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Rd, Piscataway, NJ 08854, USA. Electronic address: matthew.s.palombo@gsk.com.
Xiaoping ZhangDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Rd, Piscataway, NJ 08854, USA. Electronic address: xzhang@pharmacy.rutgers.edu.
Zoltan SzekelyDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Rd, Piscataway, NJ 08854, USA. Electronic address: zoltan@pharmacy.rutgers.edu.
Patrick J SinkoDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Rd, Piscataway, NJ 08854, USA. Electronic address: sinko@rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

ANTI-HIV COLORECTAL NANOCARRIER-BASED FOAMS FOR MUCOSAL PRE-EXPOSURE PROPHYLAXISR01AI117776 · NIAID · RUTGERS, THE STATE UNIV OF N.J. · PI SINKO, PATRICK J. · 2015 to 2018
$2.1M
Multifunctional PEG Hydrogel Nano/Microparticles for Targeted Treatment of NSCLCR01CA155061 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI SINKO, PATRICK J. · 2011 to 2015
$1.8M
Summer Research Training in Environmental Health SciencesR25ES020721 · NIEHS · RUTGERS, THE STATE UNIV OF N.J. · PI Lauren M Aleksunes, Debra L Laskin · 2011 to 2026
$1.2M
Enhancing Intestinal &Brain Uptake of Anti-AIDS Drugs.R01AI051214 · NIAID · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI SINKO, PATRICK J. · 2002 to 2005
$1.1M
NCI NIH HHS R01 CA155061NIAID NIH HHS R01 AI051214NIAID NIH HHS R01 AI117776NIEHS NIH HHS R25 ES020721
6 · The paper itself

Abstract

The feasibility of utilizing the cell surface chemokine receptor CXCR4 for human immunodeficiency virus (HIV) entry inhibition and as an intracellular portal for targeted drug delivery was evaluated. Novel DV3 ligands (1DV3, 2DV3, and 4DV3) were designed, synthesized and conjugated to various probes (fluorescein isothiocyanate (FITC) or biotin) and cargos with sizes ranging from 10 to 50 nm (polyethylene glycol (PEG), streptavidin, and a polymeric nanoparticle). 4DV3 conjugated probes inhibited HIV-1 entry into the CXCR4-expressing reporter cell line TZM-bl (IC

Indexed as

Anti-HIV AgentsBinding SitesCell LineChemotaxisDrug CarriersDrug Delivery SystemsHIV-1HIV Fusion InhibitorsHIV InfectionsHumansLigandsNanoparticlesReceptors, CXCR4Signal TransductionAnti-HIV AgentsCXCR4 protein, humanDrug CarriersHIV Fusion InhibitorsLigandsReceptors, CXCR4Allosteric enhancerAMD3100CXCR4DV3HIV-1 entry inhibitorNanocarrierTargeted drug delivery

Identifiers

PMID29894816
PMCPMC6286870
OpenAlexW2806089079

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.